Use of IKK epsilon inhibitors to activate NFAT and T cell response
AssigneeUniversity of Southern California
InventorsPinghui Feng, Junjie Zhang, Hao Feng
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compositions and methods of activating nuclear factor of activated T cells (NFAT) and T cell response by inhibiting IKKε.
Claims14
A method for suppressing, repressing, or ameliorating cancer in a subject, the method comprising administering to the subject an IKKε inhibitor, wherein the IKKε inhibitor comprises a polynucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO:
- 2.
A method of increasing NFAT activation in a subject, the method comprising administering to the subject an IKKε inhibitor comprising a polynucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO:
- 2.
A method of increasing NFAT activation in a subject, the method comprising administering to the subject an IKKε inhibitor comprising an inhibitory RNA that targets IKKε, wherein CD8 T cell response is increased relative to a control.
A method of increasing T cell response in a subject, the method comprising administering to the subject an IKKε inhibitor comprising an inhibitory RNA that targets IKKε, wherein CD8 T cell response is increased relative to a control.
A method of increasing NFAT activation and T cell response in a subject, the method comprising administering to the subject an IKKε inhibitor comprising an inhibitory RNA that targets IKKε, wherein CD8 T cell response is increased relative to a control.
A method of increasing T cell response in a subject, the method comprising administering to the subject an IKKε inhibitor comprising a polynucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO:
- 2.
A method of increasing NFAT activation and T cell response in a subject, the method comprising administering to the subject an IKKε inhibitor comprising a polynucleotide sequence selected from SEQ ID NO:1 or SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.